文献速递生殖医学

预处理抗苗勒管激素水平与促性腺激素/宫腔内人工授精周期卵巢刺激结局的关系

Pretreatment antimüllerian hormone levels and outcomes of ovarian stimulation with gonadotropins/intrauterine insemination cycles.
PubMed 文献 · Fertil Steril · 2021-04-03

这项回顾性队列研究纳入1861个促性腺激素刺激/宫腔内人工授精周期,按AMH水平分为低、中、高三组。结果显示中、高AMH组临床妊娠概率高于低AMH组,低AMH组自然流产发生率风险比在未调整模型中较高。

要点

  • 与低AMH组相比,中、高AMH组临床妊娠概率更高。
  • 低AMH组自然流产风险比在未调整模型中较高。
  • AMH可能影响促性腺激素/IUI周期的临床妊娠概率。

核心结论

  • 在促性腺激素刺激/宫腔内人工授精周期中,AMH似乎影响获得临床妊娠的概率。
  • 结果还提示AMH可能独立于年龄对自然流产风险有负面影响。

研究设计与样本

  • 回顾性队列研究,共1861个促性腺激素刺激/宫腔内人工授精周期。
  • 按AMH水平分为三组:低组<25百分位(<0.7 ng/mL),中组≥25且<75百分位(0.7-4.4 ng/mL),高组≥75百分位(≥4.5 ng/mL)。

主要发现

  • 在未调整和调整模型中,中、高AMH组相比低AMH组,3个周期内临床妊娠风险比分别为1.55(95%CI 1.05-2.29)和1.85(95%CI 1.22-2.81)。
  • 在未调整和调整模型中,中、高AMH组相比低AMH组,6个周期内临床妊娠风险比分别为1.71(95%CI 1.17-2.48)和2.12(95%CI 1.42-3.16)。
  • 未调整模型中,低AMH组自然流产发生率风险比为2.17(95%CI 1.11-4.24);调整年龄后为1.83(95%CI 0.93-3.60)。
  • 在无多囊卵巢综合征亚组中,未调整和调整后自然流产风险比分别为1.94(95%CI 0.97-3.88)和1.74(95%CI 0.86-3.49)。

临床怎么用

  • 对于接受促性腺激素刺激/宫腔内人工授精的患者,可参考AMH水平评估临床妊娠概率。
  • 低AMH水平可能与较高的自然流产风险相关,咨询时需考虑年龄因素。

局限性

  • 回顾性队列设计。
  • 自然流产风险比在调整年龄后置信区间包含1。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association, if any, between serum antimüllerian hormone (AMH) levels and probability of clinical pregnancy and spontaneous abortion (SAB) in the infertility setting. DESIGN: Retrospective cohort study. SETTING: Academic fertility center. PATIENT(S): A total of 1,861 gonadotropin stimulation/intrauterine insemination cycles stratified by AMH levels into 3 groups: Low, <25th percentile (<0.7 ng/mL); Middle, ≥25th and <75th percentile (0.7-4.4 ng/mL); and High, ≥75th percentile (≥4.5 ng/mL). INTERVENTION(S): Intrauterine insemination after stimulation with gonadotropins. MAIN OUTCOME MEASURE(S): Cumulative probability of clinical pregnancy over a maximum of 3 and/or 6 cycles and SAB incidence risk rate (IRR). The Kaplan-Meier failure function (log rank test), Cox proportional hazards models, and multilevel mixed-effects Poisson regression models were performed to compare outcomes among the AMH groups. RESULT(S): Overall, in both unadjusted and adjusted models, the probability of achieving a clinical pregnancy was higher in the Middle and High AMH groups compared with that in the Low AMH group, both over 3 (hazard ratios [95% confidence interval], 1.55 [1.05-2.29] and 1.85 [1.22-2.81], respectively) and 6 (1.71 [1.17-2.48] and 2.12 [1.42-3.16], respectively) cycles. In the unadjusted models, the SAB IRR was higher among the Low AMH group (IRR [95% confidence interval], 2.17 (1.11-4.24]), with the relationship persisting after adjusting for age (1.83 [0.93-3.60]). When the SAB IRR were calculated separately for the subpopulations with and without polycystic ovary syndrome, a similar relationship was noted among the latter in the unadjusted (1.94 [0.97-3.88]) and adjusted (1.74 [0.86-3.49]) analyses. CONCLUSION(S): In women undergoing gonadotropin stimulation/intrauterine insemination, AMH appears to affect the probability of achieving a clinical pregnancy. A possible negative impact, independent of age, on the risk of SAB was also suggested.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Vagios S, Hsu JY, Sacha CR, et al. Pretreatment antimüllerian hormone levels and outcomes of ovarian stimulation with gonadotropins/intrauterine insemination cycles. Fertil Steril. 2021. PMID: 33823994. doi:10.1016/j.fertnstert.2021.02.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。